pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,776 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints640BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps39globenewswire health28fda recalls
therapy area
allOncology5007Rare Disease854Cardiology802Hematology772Immunology736Psychiatry & CNS582Pulmonology
  • Microbiome startup raises $48M for immunotherapy and malnutrition treatments
    Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop. A biotech startup has studied th…
    Endpoints · 2mo ago↗ source
  • J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
    Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…
    Endpoints · 2mo ago↗ source
  • Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia
    Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.
← prev
page 63 of 72
next →
24
fda press21
fda medwatch18
573
Vaccines517
Endocrinology & Metabolism293
Ophthalmology265
Infectious Disease253
Nephrology239
onclive · 2mo ago
↗ source
  • Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
    Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.
    onclive · 2mo ago↗ source
  • Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want
    Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field'…
    Endpoints · 2mo ago↗ source
  • Healthcare organizations are increasingly building their own AI tools
    Big healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to find…
    Endpoints · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
    HHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressants
    STAT · 2mo ago↗ source
  • Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
    Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.
    onclive · 2mo ago↗ source
  • New Endometrial Targets Beyond HER2
    Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and oth…
    onclive · 2mo ago↗ source
  • Coordinating Care in Multiple Myeloma Across Practice Settings
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression
    In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase…
    onclive · 2mo ago↗ source
  • New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons
    Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.
    onclive · 2mo ago↗ source
  • What you need to know about hantavirus (don’t panic)
    The latest on the abortion pill, paternal deaths, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
    Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The…
    Endpoints · 2mo ago↗ source
  • STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
    A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.
    STAT · 2mo ago↗ source
  • Opinion: The ‘brain drain’ narrative about health professionals misses half of the story
    52 health professionals returned home to 43 countries. Here are the unexpected challenges and opportunities they faced.
    STAT · 2mo ago↗ source
  • Opinion: The cruise ship hantavirus outbreak is a warning sign to the U.S.
    Leaving the WHO means the U.S. lacks access to necessary information about infectious disease.
    STAT · 2mo ago↗ source
  • STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight
    A top Republican is asking if the AMA's codes are helping to fuel health care fraud.
    STAT · 2mo ago↗ source
  • STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
    A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
    STAT · 2mo ago↗ source
  • Vertex drops mRNA cystic fibrosis program over 'tolerability' issues
    Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering th…
    Endpoints · 2mo ago↗ source
  • STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
    France's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.
    STAT · 2mo ago↗ source
  • Opinion: Mifepristone court ruling makes drug development riskier for everyone
    The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.
    STAT · 2mo ago↗ source
  • FDA search for new CBER head focused on small group of final candidates
    The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three or four final candidates, according to a person familiar with the matter. The agency ho…
    Endpoints · 2mo ago↗ source
  • Supreme Court restores mifepristone access by mail
    The Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court’s stay. The decision Monday came after makers of the pill asked for an immediate response to a ruling ...
    Endpoints · 2mo ago↗ source
  • Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
    The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to upend one of the main ways abortion is provided across the…
    STAT · 2mo ago↗ source